Sungening

Sungening, based in Shenzhen, China, is a biotechnology company dedicated to pioneering innovative drug development, particularly through its advanced AI-driven cyclic peptide technologies. Founded in 2021, Shenzhen Sungening Biotechnology Co. , Ltd. specializes in the research and development of novel pharmaceuticals.

The company has not undergone any significant pivots or changes in strategy. Its headquarters is located in Shenzhen, China. The company has successfully closed one funding deal, with the most recent being in February 2026. Shenzhen Sungening Biotechnology Co.

, Ltd. specializes in the development of innovative drugs, particularly focusing on 'AI + cyclic peptide' technologies. The company's core product offerings revolve around its proprietary SunCyclix™ cyclic peptide platform, which utilizes advanced mRNA display technologies, AI-driven molecular simulations, and cyclic peptide optimization techniques. The primary therapeutic areas targeted include anti-infective treatments and metabolic disorders, with current research pipelines showcasing multiple drug candidates at varying stages of development.

Notably, the company is concentrating on developing best-in-class candidates for invasive aspergillosis and candidiasis, with one product already advancing through clinical trials in both China and the United States. The company's products aim to deliver more precise and safer treatment options for patients suffering from these conditions, primarily targeting markets in North America and globally. The revenue model for Shenzhen Sungening Biotechnology is structured around partnerships and collaborations within the pharmaceutical industry, focusing on business-to-business transactions. The company’s flagship products, which include cyclic peptide-based therapies for high cholesterol and fungal infections, are offered to healthcare providers, research institutions, and pharmaceutical companies.

Revenue is generated through strategic alliances, licensing agreements, and commercialization, particularly as the company progresses its drug candidates through clinical development phases. Pricing structures for these therapeutic solutions are expected to reflect industry standards for advanced biotech products, promoting access for healthcare providers and ultimately benefiting patients in need of innovative treatments. Looking ahead, Sungening is set to leverage its recent funding from Shenzhen Longgang District Guidance Fund Investment to enhance its product development pipeline. The company aims to launch new cyclic peptide therapies and expand into North American and global markets by 2026.

The upcoming product launches are designed to address critical health needs in anti-infective treatments and metabolic disorders, aligning with its ongoing clinical trials.